TG Therapeutics announced preliminary U.S. net product revenue for BRIUMVI of $103.6 million for the fourth quarter of 2024, contributing to a full-year 2024 U.S. net product revenue of $310 million. These preliminary figures were shared during a presentation at the 43rd Annual J.P. Morgan Healthcare Conference.
Looking ahead to 2025, the company set a target for total global revenue of approximately $540 million, with U.S. net product revenue for BRIUMVI projected at approximately $525 million. This guidance reflects continued confidence in BRIUMVI's market performance and adoption.
The company also outlined key development milestones for 2025, including the planned commencement of a pivotal program for subcutaneous BRIUMVI, which aims to offer a self-administered option with every-other-month or quarterly dosing. Additionally, TG Therapeutics plans to launch pivotal trials to optimize intravenous BRIUMVI and to enroll patients with progressive MS into a Phase 1 trial for its allogeneic CD19-directed CAR-T therapy, azer-cel.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.